CapexCetaphilClindagelClobexDifferinMetrogelRosanilTri-LumaOther


Tri-Luma® Cream is the first triple-action cream for the short-term treatment of moderate to severe melasma of the face.

This powerful combination of three active ingredients is more effective than any of the individual components in reducing the darkened skin caused by melasma.*

Visible proof is seen in as little as 4 weeks, with maximum results seen in 8 weeks. This convenient, well-tolerated cream is applied nightly before bed. To learn whether Tri-Luma® Cream is right for you, visit www.triluma.com.

Melasma is a hyperpigmentation disorder of the skin and appears as dark spots or blotches on the face, forehead and neck. It is the result of excess melanin being deposited in the dermal or epidermal layers of the skin. The cause is an imbalance of hormones due to a recent pregnancy, use of oral contraceptives or hormone replacement therapy. Also known as the "mask of pregnancy," melasma occurs in 50%-70% of pregnant women and 5%-34% of women taking birth control pills.

It you think you may have melasma, use our Self-Assess Your Skin Tool to find out more. To locate a dermatologist in your area, use DermFinder.

* Data on file, Galderma Laboratories, L.P.

Tri-Luma® Cream is contraindicated in individuals with a hypersensitivity, allergy or intolerance to fluocinolone acetonide, hydroquinone or tretinoin. In clinical trials, the most frequently reported side effects were erythema, desquamation, burning, dryness and pruritus.

Mild to moderate redness, peeling, burning, dryness or itching may be experienced. People allergic to sulfites should not use Tri-Luma® Cream. Exposure to sunlight, sunlamps or UV light and extreme heat, wind or cold should be avoided. Use of sunscreen with appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.

Tri-Luma® Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma® Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticod insufficiency after withdrawal of treatment.